• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Evolus Inc.

    5/15/25 4:47:57 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    EVOLUS, INC.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    30052C107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    30052C107


    1Names of Reporting Persons

    Nantahala Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,751,343.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,751,343.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,751,343.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.90 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    30052C107


    1Names of Reporting Persons

    Wilmot B. Harkey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,751,343.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,751,343.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,751,343.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.90 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    30052C107


    1Names of Reporting Persons

    Daniel Mack
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,751,343.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,751,343.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,751,343.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.90 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    EVOLUS, INC.
    (b)Address of issuer's principal executive offices:

    520 NEWPORT CENTER DRIVE SUITE 1200 NEWPORT BEACH, CALIFORNIA, 92660
    Item 2. 
    (a)Name of person filing:

    (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, Connecticut 06840
    (c)Citizenship:

    (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    30052C107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 31, 2025, Nantahala may be deemed to be the beneficial owner of 3,751,343 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.
    (b)Percent of class:

    As of March 31, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 5.90% (2) Wilmot B. Harkey: 5.90% (3) Daniel Mack: 5.90%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (ii) Shared power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 3,751,343 Shares. (2) Wilmot B. Harkey: 3,751,343 Shares. (3) Daniel Mack: 3,751,343 Shares.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 3,751,343 Shares. (2) Wilmot B. Harkey: 3,751,343 Shares. (3) Daniel Mack: 3,751,343 Shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nantahala Capital Management, LLC
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer
    Date:05/15/2025
     
    Wilmot B. Harkey
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey
    Date:05/15/2025
     
    Daniel Mack
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack
    Date:05/15/2025
    Get the next $EOLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Evolus with a new price target

      BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus upgraded by Barclays with a new price target

      Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

      1/29/24 7:09:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Evolus with a new price target

      Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00

      6/23/22 7:38:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

      1/4/24 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

      Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:

      8/21/23 8:45:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Evolus Inc.

      SCHEDULE 13G - Evolus, Inc. (0001570562) (Subject)

      5/15/25 4:47:57 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

      SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

      5/15/25 4:30:10 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

      SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

      5/15/25 4:15:24 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Financials

    Live finance-specific insights

    See more

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

      Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense

      3/4/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:50:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:00:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/13/24 5:38:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

      Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly

      5/5/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Avelar Rui sold $33,397 worth of shares (3,385 units at $9.87), decreasing direct ownership by 0.93% to 359,082 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:50 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beaver Sandra sold $65,070 worth of shares (6,494 units at $10.02), decreasing direct ownership by 4% to 167,089 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:40 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Moatazedi David sold $155,756 worth of shares (15,787 units at $9.87), decreasing direct ownership by 3% to 492,832 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care